| NCT ID | NCT07213700 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stichting International Registry for Alzheimer's Disease and other Dementias Foundation |
| Condition | Alzheimer's Disease(AD) |
| Study Type | OBSERVATIONAL |
| Enrollment | 50,000 participants |
| Start Date | 2026-03-30 |
| Primary Completion | 2036-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50,000 participants in total. It began in 2026-03-30 with a primary completion date of 2036-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this international observational study is to evaluate long-term disease outcomes and treatment safety in people with Alzheimer's disease (PwAD), by collecting real-world data from routine clinical practice across global clinical centers. The InRAD Registry Observational Study has several aims: * To collect medical information for many years from a large group of people with Alzheimer's disease. This will be used for research, which will support improved understanding about the disease. * To enable researchers to look at the effectiveness, usefulness and safety of treatments for Alzheimer's disease. * To enable researchers to answer similar research questions and compare results in many different areas of the world. People with Alzheimer's disease who meet the eligibility criteria and agree to participate in the Study will be asked to visit their doctor (e.g. psychiatrist, geriatrician, or neurologist) at least once a year, or as frequently as is needed for their care. During or after their appointments they may be offered assessments, tests, medications, and treatments as determined by their doctor and their team. This is an observational data collection.
Eligibility Criteria
Inclusion Criteria: * Be undergoing diagnostic work-up for Alzheimer's disease (AD), OR * Have a confirmed diagnosis of AD (whether currently treated with an AD-specific treatment, or untreated), * Be attending an InRAD Center, * Have provided informed consent for long-term follow-up Exclusion Criteria: -Any patient or legal representative who is unable or unwilling to provide a signed informed consent form
Contact & Investigator
Scientific Officer
✉ office@inradnetwork.orgFrequently Asked Questions
Who can join the NCT07213700 clinical trial?
This trial is open to participants of all sexes, studying Alzheimer's Disease(AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07213700 currently recruiting?
Yes, NCT07213700 is actively recruiting participants. Contact the research team at office@inradnetwork.org for enrollment information.
Where is the NCT07213700 trial being conducted?
This trial is being conducted at Schwarzach, Austria, Leuven, Belgium, São Paulo, Brazil, Thessaloniki, Greece and 3 additional locations.
Who is sponsoring the NCT07213700 clinical trial?
NCT07213700 is sponsored by Stichting International Registry for Alzheimer's Disease and other Dementias Foundation. The trial plans to enroll 50,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.